Cohen Milstein was one of the co-lead counsel in In re Lupron Marketing and Sales Practices Litigation, No. 01-CV-10861-RGS, MDL No. 1430 (D. Mass), a class action against the manufacturer and marketers of Lupron, a prescription drug used to treat prostate cancer, endometriosis and precocious puberty. The court approved a $150 million settlement for patients, insurance companies and health and welfare benefit plans who paid for Lupron from January 1, 1985 through March 31, 2005. Plaintiffs alleged that defendants’ fraudulent scheme involved, inter alia, a scheme to artificially inflate the average wholesale price (“AWP”) of Lupron so that doctors could charge more for Lupron; giving free samples to doctors knowing they would charge patients and insurers for them; and giving valuable gifts to doctors as incentives to prescribe Lupron instead of other less costly alternatives.  You may obtain more information on the settlement, and read the notices and orders from the case, at http://www.lupronclaims.com/.